Company intelligence / Profile preview

Doloromics

Menlo Park, California, United Statesdoloromics.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Doloromics is developing precision therapeutics for chronic pain using a proprietary platform that integrates single-cell transcriptomics, proteomics, and computational biology to identify novel targets. Their lead program is nearing the IND stage. The company’s approach aims to provide safer alternatives to opioids by targeting specific molecular mechanisms underlying chronic pain. No clinical results have been reported yet as programs are preclinical/IND-enabling

Therapeutic areas: NeurologyRheumatology
Modalities: Small molecules (inferred from neuropharmaceutical focus and omics-based drug discovery)Potential for biologics or gene therapies (based on use of omics and transcriptomic/proteomic technologies, but not explicitly confirmed)
Industry: Biotech

Beyond the preview

Go deeper on Doloromics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Doloromics.

Explore the full profile